TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: l Prospective Clinical Investigation on the Acoustic Stimulation With the "Coordinated Reset of Neural Subpopulations" in the Treatment of Chronic Tinnitus
Brief Summary: There are many treatments for chronic tinnitus that have been claimed, with varying degrees of statistical reliability. None of those treatments can eradicate the tinnitus completely. Some therapies can reduce the tinnitus symptoms (loudness, annoyance) up to 30%. Thus there is still a need of new treatments that can reduce considerably the tinnitus symptoms and improve the QOL of subjects.

Trial objectives:

* The aim of this trial is the improvement of the QOL (quality of live) by reducing the Tinnitus- Symptoms of the patient.
* To confirm the efficacy and safety of the coordinated reset technology.

These objectives will be assessed:

* By subjective and objective measurements of the Tinnitus symptoms, loudness and annoyance.


Options:
A: Arm Label: Specialized Care; Type: EXPERIMENTAL; Interventions: Behavioral: Specialized Care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Specialized Care; Assigned to Arm(s): Specialized Care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: control; Type: OTHER; Interventions: Device: hearing aids with only amplification | Arm Label: sound generator; Type: EXPERIMENTAL; Interventions: Device: sound generator | Intervention Type: DEVICE; Name: sound generator; Assigned to Arm(s): sound generator | Intervention Type: DEVICE; Name: hearing aids with only amplification; Assigned to Arm(s): control
C: Arm Label: STAR2; Type: ACTIVE_COMPARATOR; Interventions: Other: reactive auditory training | Arm Label: Treasure Hunter; Type: EXPERIMENTAL; Interventions: Other: Interactive auditory training | Arm Label: Submarine; Type: EXPERIMENTAL; Interventions: Other: Interactive auditory training | Intervention Type: OTHER; Name: reactive auditory training; Assigned to Arm(s): STAR2 | Intervention Type: OTHER; Name: Interactive auditory training; Assigned to Arm(s): Submarine, Treasure Hunter
D: Arm Label: Group 1 : G_1; Type: ACTIVE_COMPARATOR; Interventions: Device: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset | Arm Label: Group 2 :G_2; Type: ACTIVE_COMPARATOR; Interventions: Device: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset | Arm Label: Group3 : G_3; Type: ACTIVE_COMPARATOR; Interventions: Device: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset | Arm Label: Group 4 : G_4; Type: ACTIVE_COMPARATOR; Interventions: Device: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset | Arm Label: Group5 : G_5; Type: PLACEBO_COMPARATOR; Interventions: Device: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset | Intervention Type: DEVICE; Name: Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset; Assigned to Arm(s): Group 1 : G_1, Group 2 :G_2, Group 4 : G_4, Group3 : G_3, Group5 : G_5

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A+ Head Start Intervention for Smoke Free Homes
Brief Summary: Environmental tobacco smoke (ETS0, also known as secondhand smoke, is the combination of smoke given off by the burning end of a tobacco product and the smoke exhaled by the smoker. Children exposed to ETS are at an increased risk of sudden infant death syndrome (SIDS), ear infections, colds, pneumonia, bronchitis and more severe asthma. ETS can also slow the growth of children's lungs and can cause them to cough, wheeze and fell breathless. The purpose of this study is to determine the effectiveness of a motivational interviewing-based program in reducing ETS exposure and improving lung health among children who are enrolled in a Head Start program and whose households include a smoker.


Options:
A: Intervention Type: BEHAVIORAL; Name: Coping-focused counseling telephone calls; Assigned to Arm(s): N/A
B: Arm Label: Hospital phone counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling | Arm Label: Fax-to-quit; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fax-to-quit | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Hospital phone counseling | Intervention Type: BEHAVIORAL; Name: Fax-to-quit; Assigned to Arm(s): Fax-to-quit
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Varenicline plus Motivational Interviewing counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Varenicline without counseling | Intervention Type: OTHER; Name: Varenicline plus Motivational Interviewing counseling; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Varenicline without counseling; Assigned to Arm(s): 2
D: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing Intervention for ETS Reduction | Arm Label: Education Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Program for ETS Reduction | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing Intervention for ETS Reduction; Assigned to Arm(s): Behavioral | Intervention Type: BEHAVIORAL; Name: Educational Program for ETS Reduction; Assigned to Arm(s): Education Only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A+ Head Start Intervention for Smoke Free Homes
Brief Summary: Environmental tobacco smoke (ETS0, also known as secondhand smoke, is the combination of smoke given off by the burning end of a tobacco product and the smoke exhaled by the smoker. Children exposed to ETS are at an increased risk of sudden infant death syndrome (SIDS), ear infections, colds, pneumonia, bronchitis and more severe asthma. ETS can also slow the growth of children's lungs and can cause them to cough, wheeze and fell breathless. The purpose of this study is to determine the effectiveness of a motivational interviewing-based program in reducing ETS exposure and improving lung health among children who are enrolled in a Head Start program and whose households include a smoker.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: School-based Care; Type: EXPERIMENTAL; Interventions: Behavioral: School-based Care | Intervention Type: BEHAVIORAL; Name: School-based Care; Assigned to Arm(s): School-based Care
B: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing Intervention for ETS Reduction | Arm Label: Education Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Program for ETS Reduction | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing Intervention for ETS Reduction; Assigned to Arm(s): Behavioral | Intervention Type: BEHAVIORAL; Name: Educational Program for ETS Reduction; Assigned to Arm(s): Education Only
C: Arm Label: Clinic Quality Improvement + Behavioral Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic Quality Improvement + Behavioral Counseling | Arm Label: Clinic Quality Improvement + Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic Quality Improvement + Attention Control | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Behavioral Counseling; Assigned to Arm(s): Clinic Quality Improvement + Behavioral Counseling | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Attention Control; Assigned to Arm(s): Clinic Quality Improvement + Attention Control
D: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention based in clinical practice guide | Intervention Type: BEHAVIORAL; Name: Brief intervention based in clinical practice guide; Assigned to Arm(s): Lifestyle counseling

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of the Effectiveness of Lithium in Subjects With Treatment-Resistant Depression and Suicide Risk. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial
Brief Summary: The principal clinical question is whether lithium is effective in reducing the risk of suicidal behaviour in subjects with treatment-resistant depression and suicide risk. Additionally aims of the study are: (a) to assess whether lithium is effective in improving depressive symptomatology in subjects with treatment-resistant depression and suicide risk; (b) to assess the tolerability profile of lithium.


Options:
A: Arm Label: Add-on Quetiapine XR+SSRI/Venlafaxine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine XR, Drug: SSRI/Venlafaxine | Arm Label: Add-on Lithium+SSRI/Venlafaxine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium carbonate, Drug: SSRI/Venlafaxine | Arm Label: Monotherapy Quetiapine XR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine XR | Intervention Type: DRUG; Name: Quetiapine XR; Assigned to Arm(s): Add-on Quetiapine XR+SSRI/Venlafaxine, Monotherapy Quetiapine XR | Intervention Type: DRUG; Name: Lithium carbonate; Assigned to Arm(s): Add-on Lithium+SSRI/Venlafaxine | Intervention Type: DRUG; Name: SSRI/Venlafaxine; Assigned to Arm(s): Add-on Lithium+SSRI/Venlafaxine, Add-on Quetiapine XR+SSRI/Venlafaxine
B: Arm Label: Drug 2mg/Drug 5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 5mg, Drug: Aripiprazole 2mg | Arm Label: Placebo/Drug 2mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 2mg, Drug: Placebo | Arm Label: Placebo/Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole 5mg; Assigned to Arm(s): Drug 2mg/Drug 5mg | Intervention Type: DRUG; Name: Aripiprazole 2mg; Assigned to Arm(s): Drug 2mg/Drug 5mg, Placebo/Drug 2mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Drug 2mg, Placebo/Placebo
C: Arm Label: lithium plus usual care; Type: EXPERIMENTAL; Interventions: Drug: lithium | Arm Label: usual care without lithium therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: usual care | Intervention Type: DRUG; Name: lithium; Assigned to Arm(s): lithium plus usual care | Intervention Type: DRUG; Name: usual care; Assigned to Arm(s): usual care without lithium therapy
D: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Safety and Efficacy of Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism in Medical Patients With Renal Insufficiency
Brief Summary: Fondaparinux is a parenteral anticoagulant drug and is approved for the prevention of venous thromboembolism in high risk medical patients. A relevant proportion of medical patients have moderate to severe renal insufficiency, which is an independent risk factor for bleeding. This risk may be further increased when low molecular weight heparin or fondaparinux are administered in patients with severe renal insufficiency, defined by a creatinine clearance of lower than 30 mL/min. No clear indications are available to reduce such risk in patients who require thromboprophylaxis. A lower dose of fondaparinux, 1.5 mg daily, has been recently approved for the prevention of venous thromboembolism in the specific population of patients with a creatinine clearance between 20 and 50 mL/min (European Marketing Authorization). However, there are to our knowledge no clinical studies that have assessed the safety and efficacy of this reduced dosage in medical patients.


Options:
A: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Placebo (for warfarin), Drug: Avidin | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Placebo (for idrabiotaparinux), Drug: Placebo (for avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Placebo (for idrabiotaparinux); Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Placebo (for warfarin); Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for avidin); Assigned to Arm(s): Warfarin
B: Arm Label: fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: fondaparinux | Intervention Type: DRUG; Name: fondaparinux; Assigned to Arm(s): fondaparinux
C: Intervention Type: DRUG; Name: SR34006 (idraparinux sodium) Injection; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin K antagonist (warfarin or acenocoumarol) tablets; Assigned to Arm(s): N/A
D: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Avidin, Drug: Placebo (for Avidin) | Arm Label: Idraparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idraparinux sodium, Drug: Placebo (for Avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Idraparinux sodium; Assigned to Arm(s): Idraparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for Avidin); Assigned to Arm(s): Idrabiotaparinux, Idraparinux

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder.
Brief Summary: This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).


Options:
A: Intervention Type: DRUG; Name: Tolterodine ER 4mg QD; Assigned to Arm(s): N/A
B: Arm Label: Fesoterodine; Type: EXPERIMENTAL; Interventions: Drug: Fesoterodine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fesoterodine; Assigned to Arm(s): Fesoterodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VESIcare® | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: VESIcare®; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: 1: Solifenacin 5 mg + Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate, Drug: Mirabegron, Drug: Placebo to match mirabegron | Arm Label: 2: Solifenacin 5 mg + Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate, Drug: Mirabegron, Drug: Placebo to match mirabegron | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 4: Solifenacin 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 5:Mirabegron 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron, Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 6: Mirabegron 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron, Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 4: Solifenacin 5 mg | Intervention Type: DRUG; Name: Mirabegron; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg | Intervention Type: DRUG; Name: Placebo to match solifenacin succinate; Assigned to Arm(s): 3: Placebo, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg | Intervention Type: DRUG; Name: Placebo to match mirabegron; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 3: Placebo, 4: Solifenacin 5 mg, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Study of Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Hospitalized Patients With Exacerbation of Cystic Fibrosis
Brief Summary: Cystic fibrosis (CF) lung disease is characterized by chronic bacterial colonization and recurrent infection of the airways. Lowering the airway surface liquid (ASL) salt concentration has been shown to increase activity of salt sensitive antimicrobial peptides.

Xylitol is a 5-carbon sugar that can lower the ASL salt concentration, thus enhancing innate immunity. In this study, the investigators propose to test the safety and tolerability of aerosolized xylitol used daily for 2 weeks in subjects with cystic fibrosis. In a pilot, 2-week study, 60 subjects with cystic fibrosis with an FEV1(Forced expiratory volume in 1 second ) \>30% predicted will be randomized to receive aerosolized 7% hypertonic saline (5 ml) or 15% xylitol, (5 ml) twice a day for 14 days. The primary outcomes will be safety as assessed by FEV1 change from baseline, adverse events and respiratory symptom score. Outcomes for trend in efficacy include density of colonization of sputum, time to next exacerbation, sputum cytokines and revised CF quality of life questionnaire.


Options:
A: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer
B: Arm Label: 7% saline; Type: EXPERIMENTAL; Interventions: Drug: 7% saline | Arm Label: 0.12% saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.12% saline | Intervention Type: DRUG; Name: 0.12% saline; Assigned to Arm(s): 0.12% saline | Intervention Type: DRUG; Name: 7% saline; Assigned to Arm(s): 7% saline
C: Arm Label: 7% Hypertonic saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypertonic saline | Arm Label: Hypertonic xylitol; Type: EXPERIMENTAL; Interventions: Drug: Xylitol | Intervention Type: DRUG; Name: Xylitol; Assigned to Arm(s): Hypertonic xylitol | Intervention Type: DRUG; Name: Hypertonic saline; Assigned to Arm(s): 7% Hypertonic saline
D: Arm Label: Group A; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group B; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group C; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group D; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group E; Type: N/A; Interventions: Behavioral: Qualitative Interview | Intervention Type: BEHAVIORAL; Name: Qualitative Interview; Assigned to Arm(s): Group A, Group B, Group C, Group D, Group E

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sustained Therapeutic Effects of Percutaneous Tibial Nerve Stimulation
Brief Summary: This is a modified extension study to the SUmiT protocol UPC082008 (NCT00534521) to observe and evaluate long term therapy with PTNS on overactive bladder symptoms. Subjects must have completed the 12 weekly treatments of the original protocol, the 13 week follow up assessment, be randomized to the PTNS arm, and be considered a positive responder with moderate or marked improvement in the SUmiT Trial to be enrolled in this study. All consenting responders will continue with active PTNS therapy at an initially prescribed protocol for approximately 3 months followed by individualized symptom-based frequency of visits as determined by the subject along with their treating clinician, for up to a total of 33 months post initial 12-week therapy for a total of 3 years.


Options:
A: Arm Label: Percutaneus Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneus Stimulation | Arm Label: Transcutaneous Stimulation; Type: EXPERIMENTAL; Interventions: Device: Transcutaneous Stimulation | Intervention Type: DEVICE; Name: Transcutaneous Stimulation; Assigned to Arm(s): Transcutaneous Stimulation | Intervention Type: PROCEDURE; Name: Percutaneus Stimulation; Assigned to Arm(s): Percutaneus Stimulation
B: Arm Label: Urgent PC; Type: ACTIVE_COMPARATOR; Interventions: Device: Urgent PC | Intervention Type: DEVICE; Name: Urgent PC; Assigned to Arm(s): Urgent PC
C: Arm Label: Urgent PC treatment arm; Type: EXPERIMENTAL; Interventions: Device: Urgent PC Neuromodulation System, Drug: Tolterodine | Intervention Type: DEVICE; Name: Urgent PC Neuromodulation System; Assigned to Arm(s): Urgent PC treatment arm | Intervention Type: DRUG; Name: Tolterodine; Assigned to Arm(s): Urgent PC treatment arm
D: Arm Label: Urgent PC; Type: ACTIVE_COMPARATOR; Interventions: Device: Urgent PC Neuromodulation System | Arm Label: Sham / Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urgent PC Neuromodulation System; Assigned to Arm(s): Urgent PC

Answer: B